Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of NHS England’s decision not to commission abiraterone acetate plus prednisone/prednisolone for men with high risk non metastatic prostate cancer on health equity for Black men.

NHS England develops an Equality and Health Inequalities Impact Assessment (EHIA) for policy propositions included in its Policy Work Programme. The EHIA for abiraterone acetate plus prednisone for hormone sensitive non-metastatic prostate cancer noted that incidence rates for prostate cancer are higher in the black ethnic group, compared with the white ethnic group, in males in England. Commissioning decisions for abiraterone acetate plus prednisone/prednisolone apply equally to all individuals with high risk non metastatic prostate cancer regardless of race or ethnicity.

Incidence rates for prostate cancer are higher in the black ethnic group, compared with the white ethnic group, in males in England. To address this inequality, the Government has invested £16 million in the £42 million United Kingdom-wide TRANSFORM trial, led by Prostate Cancer UK, which aims to identify new ways of detecting prostate cancer at an earlier stage, including in men without symptoms. The trial will ensure that at least 10% of participants are Black men, reflecting their higher risk and the importance of ensuring new tests are effective across all groups.